Latest Posts › Amgen

Share:

Broad Genus Patents Must Be Enabled over the Full Scope of the Claims

Amgen Inc. et al. v. Sanofi et al., No. 22-157 (U.S. 2023) - The U.S. Supreme Court, in a unanimous decision, has affirmed the Federal Circuit’s decision invalidating Amgen’s patent claims covering a genus of antibodies...more

Federal Circuit Finds Antibodies Claimed by Epitope Binding Pose a High Hurdle in Fulfilling the Enablement Requirement

Amgen Inc. v. Sanofi, No. 20-1074 (Fed. Cir. 2021) The Federal Circuit recently issued a precedential decision on the validity of antibody epitope claims covering Amgen's Repatha® (evolocumab) product. The court found...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide